34 -5 (91) 2026 - Abdullaev Sh.S., Xaydarova N.B. - CARDIOMETABOLIC DISORDERS IN PATIENTS WITH MAFLD: MODERN APPROACHES TO RISK ASSESSMENT

CARDIOMETABOLIC DISORDERS IN PATIENTS WITH MAFLD: MODERN APPROACHES TO RISK ASSESSMENT

Abdullaev Sh.S. - Andijan State Medical Institute

Xaydarova N.B. - Andijan State Medical Institute

Dauletbaev B.K. - Andijan State Medical Institute

Valieva Z.S. - Andijan State Medical Institute

Abduraxmanov M.G. - Andijan State Medical Institute

Resume

Metabolic dysfunction-associated fatty liver disease (MAFLD) is one of the most common chronic liver diseases and is closely associated with the development of cardiometabolic disorders. Patients with MAFLD have a significantly increased risk of cardiovascular diseases, insulin resistance, type 2 diabetes mellitus, arterial hypertension, and dyslipidemia. Modern approaches to risk assessment are based on a comprehensive evaluation of clinical, biochemical, and instrumental indicators, including the assessment of visceral obesity, inflammatory markers, liver fibrosis, and cardiovascular risk factors. Non-invasive diagnostic methods such as elastography, fibrosis indices, and contemporary cardiometabolic risk scoring systems play an important role in early detection and monitoring. Early diagnosis of MAFLD and timely correction of risk factors can reduce the progression of the disease and prevent cardiovascular complications. A comprehensive multidisciplinary approach remains essential in the management of patients with MAFLD.

Keywords: Metabolic dysfunction-associated fatty liver disease (MAFLD); cardiometabolic disorders; cardiovascular risk; insulin resistance; type 2 diabetes mellitus; visceral obesity; liver fibrosis; dyslipidemia; risk assessment; non-invasive diagnostics.

First page

195

Last page

198

For citation:Abdullaev Sh.S., Xaydarova N.B., Dauletbaev B.K., Valieva Z.S., Abduraxmanov M.G. - CARDIOMETABOLIC DISORDERS IN PATIENTS WITH MAFLD: MODERN APPROACHES TO RISK ASSESSMENT//New Day in Medicine 5(91)2026 195-198 https://newdayworldmedicine.com/en/new_day_medicine/5-91-2026

List of References

  1. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73(1):202-209. DOI: 10.1016/j.jhep.2020.03.039.
  2. Eslam M, Sanyal AJ, George J. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999-2014. DOI: 10.1053/j.gastro.2019.11.312.
  3. Mantovani A, Byrne CD, Zheng MH, Targher G. Risk of nonalcoholic fatty liver disease in individuals with type 1 diabetes: A meta-analysis. Diabetes Care. 2021;44(2):480-487. DOI: 10.2337/dc20-1930.
  4. Tilg H, Adolph TE, Moschen AR. Multiple hits hypothesis in NAFLD—revisited after a decade. Hepatology. 2021;73(3):833-842. DOI: 10.1002/hep.31518.
  5. Tilg H, Effenberger M, Stadlmann A. NAFLD and MAFLD in 2021: Debates and consensus. Nat Rev Gastroenterol Hepatol. 2021;18(5):361-368. DOI: 10.1038/s41575-021-00435-4.
  6. Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11-20. DOI: 10.1038/nrgastro.2017.109.
  7. Younossi ZM, Stepanova M, Ong JP, et al. Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates. Clin Gastroenterol Hepatol. 2020;18(3):580-588. DOI: 10.1016/j.cgh.2019.07.013.

    file

    download